Get the Stockscreener App
5.39
4.05%
0.21
After Hours:
5.34
-0.05
-0.93%
Protara Therapeutics Inc stock is traded at $5.39, with a volume of 994.06K.
It is up +4.05% in the last 24 hours and up +133.33% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$5.18
Open:
$5.12
24h Volume:
994.06K
Relative Volume:
0.46
Market Cap:
$184.98M
Revenue:
-
Net Income/Loss:
$-42.05M
P/E Ratio:
-0.9074
EPS:
-5.94
Net Cash Flow:
$-35.26M
1W Performance:
-9.87%
1M Performance:
+133.33%
6M Performance:
+123.65%
1Y Performance:
+196.15%
1-Day Range:
$5.01
$5.41
1-Week Range:
$4.91
$5.98
52-Week Range:
$1.595
$10.48
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.39 | 184.98M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
Protara Therapeutics Inc Stock (TARA) Latest News
Velan Capital Investment Management LP Increases Stake in Protara Therapeutics Inc - GuruFocus.com
Flatiron-based drug company raises $100M for cancer treatment - Crain's New York Business
Protara Therapeutics: Rising From The Ashes (NASDAQ:TARA) - Seeking Alpha
Protara Therapeutics Raises $100M in Stock Offering - TipRanks
Protara Announces Closing of $100 Million Public Offering - GlobeNewswire
SEC Form 424B5 filed by Protara Therapeutics Inc. - Quantisnow
Protara Therapeutics Secures Massive $100M Public Offering to Advance TARA-002 Development - StockTitan
Protara Therapeutics: Carving New Roads In Bladder Cancer (TARA) - Seeking Alpha
Protara: Six-Month NMIBC Treatment Data Bodes Well For Mid-2025 Catalyst - Seeking Alpha
Protara announces public offering to fund clinical programs By Investing.com - Investing.com Canada
Protara Therapeutics drops 6%, prices $100M offering - MSN
Protara Announces Pricing of $100 Million Public Offering - citybiz
Protara Therapeutics Launches Massive $100M Public Offering to Advance TARA-002 Development - StockTitan
Protara Announces Proposed Public Offering - The Manila Times
Protara announces public offering to fund clinical programs - Investing.com
Protara Therapeutics Launches Public Offering to Advance TARA-002 Clinical Development - StockTitan
Protara Therapeutics Stock Doubles On Promising Bladder Cancer Trial Data: Retail Buzz Spikes - MSN
HC Wainwright Reiterates Buy Rating for Protara Therapeutics (NASDAQ:TARA) - Defense World
Protara Therapeutics (STU:1KPA) Enterprise Value : €42.66 Mil (As of Dec. 07, 2024) - GuruFocus.com
Protara Therapeutics (NASDAQ:TARA) Earns Buy Rating from Guggenheim - MarketBeat
Protara Therapeutics' (TARA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most - Yahoo Finance
TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy - Yahoo Finance
Protara, CG Oncology Tout Promising Bladder Cancer Outcomes - BioSpace
Protera Therapeutics stock remains Buy-rated after promising TARA-002 Phase II results - Investing.com Canada
Protara cell therapy impresses in non-muscle invasive bladder cancer - FirstWord Pharma
TARA stock soars to 52-week high, touches $9.45 amid robust gains - Investing.com Australia
TARA-002 shows promise in bladder cancer trial By Investing.com - Investing.com South Africa
Protara shares spike after cell therapy shows high response rate, no severe side effects in bladder cancer trial - Fierce Biotech
Protara Therapeutics (FRA:1KPA) EV-to-Revenue : (As of Dec. 05, 2024) - GuruFocus.com
Protara Therapeutics (FRA:1KPA) 5-Day RSI : 55.72 (As of Dec. 05, 2024) - GuruFocus.com
Stock market news: Arcadia Biosciences +186.66%, Protara Therapeutics +101.69% among top gainers during mid day trading - Business Upturn
Protara, CG climb bladder ladder with SUO cancer findings - BioWorld Online
Why Is Protara Therapeutics Stock Skyrocketing Over 100% On Thursday? - Benzinga
Stock market today: Arcadia Biosciences +153.62%, Protara Therapeutics +133.20% among top gainers in early trading - Business Upturn
Protara Therapeutics Reports Promising Phase 2 Trial Results - TipRanks
Protara Therapeutics shares surge on positive trial results - Investing.com
Protara Therapeutics shares surge on positive trial results By Investing.com - Investing.com UK
Protara Therapeutics, Inc. Announces Positive Results from the Ongoing Phase 2 Advanced Advanced-2 Trial of TARA-002 in Patients with NMIBC - Marketscreener.com
Protara Therapeutics Shares Soar on Positive Data for Bladder Cancer Treatment Trials - MarketWatch
Adf Group Inc Sv (DRX-T) QuotePress Release - The Globe and Mail
Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC - The Manila Times
Protara's TARA-002 Shows Breakthrough 72% Response Rate in Bladder Cancer Trial Results - StockTitan
TARAProtara Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Protara Therapeutics to Host Conference Call and Webcast to - GlobeNewswire
Protara Therapeutics to Present Phase 2 Bladder Cancer Trial Data at Key Oncology Meeting - StockTitan
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Protara Therapeutics (FRA:1KPA) 3-Year FCF Growth Rate : 0.40% (As of Sep. 2024) - GuruFocus.com
Protara Therapeutics (STU:1KPA) EV-to-Revenue : (As of Nov. 26, 2024) - GuruFocus.com
Protara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation - Simply Wall St
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protara Therapeutics Inc Stock (TARA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Sep 11 '24 |
Sale |
1.71 |
32,600 |
55,880 |
51,500 |
| Opaleye Management Inc. | 10% Owner |
Sep 09 '24 |
Sale |
1.89 |
36,492 |
69,141 |
54,600 |
| Opaleye Management Inc. | 10% Owner |
Sep 10 '24 |
Sale |
1.77 |
25,500 |
45,110 |
53,100 |
| Opaleye Management Inc. | 10% Owner |
Jul 16 '24 |
Sale |
2.44 |
11,396 |
27,828 |
56,500 |
| Opaleye Management Inc. | 10% Owner |
Jul 11 '24 |
Sale |
2.40 |
47,993 |
115,346 |
60,000 |
| Opaleye Management Inc. | 10% Owner |
Jul 10 '24 |
Sale |
2.31 |
18,061 |
41,685 |
75,000 |
| Opaleye Management Inc. | 10% Owner |
Jul 09 '24 |
Sale |
2.21 |
8,497 |
18,811 |
80,000 |
| Opaleye Management Inc. | 10% Owner |
Jul 01 '24 |
Sale |
2.12 |
8,288 |
17,598 |
87,500 |
| Opaleye Management Inc. | 10% Owner |
Jun 27 '24 |
Sale |
2.26 |
46,574 |
105,169 |
90,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 28 '24 |
Sale |
2.07 |
17,994 |
37,334 |
85,000 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):